ARTIVION INC (AORT) Stock Fundamental Analysis
USA - NYSE:AORT - US2289031005 - Common Stock
41.36 USD
+1.41 (+3.53%)
41.36 USD
0 (0%)
Overall AORT gets a fundamental rating of 4 out of 10. We evaluated AORT against 191 industry peers in the Health Care Equipment & Supplies industry. AORT has an average financial health and profitability rating. AORT is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
AORT had negative earnings in the past year.
AORT had a positive operating cash flow in the past year.
AORT had negative earnings in each of the past 5 years.
In multiple years AORT reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -2.13%, AORT is in the better half of the industry, outperforming 68.06% of the companies in the same industry.
With a decent Return On Equity value of -4.26%, AORT is doing good in the industry, outperforming 68.59% of the companies in the same industry.
The Return On Invested Capital of AORT (2.15%) is better than 70.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.13% | ||
| ROE | -4.26% | ||
| ROIC | 2.15% |
ROA(3y)-2.68%
ROA(5y)-2.4%
ROE(3y)-7.46%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AORT's Operating Margin of 5.18% is fine compared to the rest of the industry. AORT outperforms 70.16% of its industry peers.
AORT's Operating Margin has improved in the last couple of years.
AORT has a Gross Margin of 63.99%. This is in the better half of the industry: AORT outperforms 67.02% of its industry peers.
AORT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.18% | ||
| PM (TTM) | N/A | ||
| GM | 63.99% |
OM growth 3Y31.35%
OM growth 5Y5.5%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so AORT is destroying value.
The number of shares outstanding for AORT has been increased compared to 1 year ago.
The number of shares outstanding for AORT has been increased compared to 5 years ago.
Compared to 1 year ago, AORT has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.62 indicates that AORT is not in any danger for bankruptcy at the moment.
AORT's Altman-Z score of 3.62 is fine compared to the rest of the industry. AORT outperforms 72.77% of its industry peers.
The Debt to FCF ratio of AORT is 28.63, which is on the high side as it means it would take AORT, 28.63 years of fcf income to pay off all of its debts.
AORT's Debt to FCF ratio of 28.63 is fine compared to the rest of the industry. AORT outperforms 68.59% of its industry peers.
AORT has a Debt/Equity ratio of 0.52. This is a neutral value indicating AORT is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.52, AORT is doing worse than 61.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 28.63 | ||
| Altman-Z | 3.62 |
ROIC/WACC0.26
WACC8.35%
2.3 Liquidity
A Current Ratio of 4.78 indicates that AORT has no problem at all paying its short term obligations.
The Current ratio of AORT (4.78) is better than 74.35% of its industry peers.
AORT has a Quick Ratio of 3.48. This indicates that AORT is financially healthy and has no problem in meeting its short term obligations.
AORT's Quick ratio of 3.48 is fine compared to the rest of the industry. AORT outperforms 70.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.78 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
AORT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.12%.
Looking at the last year, AORT shows a small growth in Revenue. The Revenue has grown by 7.44% in the last year.
AORT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.06% yearly.
EPS 1Y (TTM)-12.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%260%
Revenue 1Y (TTM)7.44%
Revenue growth 3Y9.14%
Revenue growth 5Y7.06%
Sales Q2Q%15.26%
3.2 Future
Based on estimates for the next years, AORT will show a very strong growth in Earnings Per Share. The EPS will grow by 46.79% on average per year.
AORT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.19% yearly.
EPS Next Y126.84%
EPS Next 2Y75.59%
EPS Next 3Y50.72%
EPS Next 5Y46.79%
Revenue Next Year11.74%
Revenue Next 2Y11.27%
Revenue Next 3Y11.48%
Revenue Next 5Y11.19%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AORT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 88.81, AORT can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, AORT is valued a bit cheaper than 67.02% of the companies in the same industry.
AORT is valuated expensively when we compare the Price/Forward Earnings ratio to 22.88, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 88.81 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AORT is valued a bit cheaper than the industry average as 67.02% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of AORT indicates a somewhat cheap valuation: AORT is cheaper than 67.02% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 254.65 | ||
| EV/EBITDA | 47.71 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AORT's earnings are expected to grow with 50.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y75.59%
EPS Next 3Y50.72%
5. Dividend
5.1 Amount
AORT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
41.36
+1.41 (+3.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners91.56%
Inst Owner ChangeN/A
Ins Owners4.91%
Ins Owner Change-1.55%
Market Cap1.95B
Analysts83.08
Price Target43.25 (4.57%)
Short Float %2.59%
Short Ratio2.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1009.98%
Min EPS beat(2)91.71%
Max EPS beat(2)1928.24%
EPS beat(4)3
Avg EPS beat(4)376.32%
Min EPS beat(4)-537.25%
Max EPS beat(4)1928.24%
EPS beat(8)5
Avg EPS beat(8)158.13%
EPS beat(12)8
Avg EPS beat(12)112.3%
EPS beat(16)10
Avg EPS beat(16)39.11%
Revenue beat(2)2
Avg Revenue beat(2)2.37%
Min Revenue beat(2)2.16%
Max Revenue beat(2)2.59%
Revenue beat(4)2
Avg Revenue beat(4)-0.38%
Min Revenue beat(4)-5.37%
Max Revenue beat(4)2.59%
Revenue beat(8)5
Avg Revenue beat(8)0.72%
Revenue beat(12)7
Avg Revenue beat(12)0.63%
Revenue beat(16)10
Avg Revenue beat(16)0.53%
PT rev (1m)29.61%
PT rev (3m)31.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-31.44%
EPS NY rev (1m)2.85%
EPS NY rev (3m)17.04%
Revenue NQ rev (1m)0.96%
Revenue NQ rev (3m)2.73%
Revenue NY rev (1m)2.48%
Revenue NY rev (3m)2.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 88.81 | ||
| P/S | 4.82 | ||
| P/FCF | 254.65 | ||
| P/OCF | 99.3 | ||
| P/B | 4.65 | ||
| P/tB | 254.75 | ||
| EV/EBITDA | 47.71 |
EPS(TTM)-0.37
EYN/A
EPS(NY)0.47
Fwd EY1.13%
FCF(TTM)0.16
FCFY0.39%
OCF(TTM)0.42
OCFY1.01%
SpS8.58
BVpS8.9
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.13% | ||
| ROE | -4.26% | ||
| ROCE | 2.72% | ||
| ROIC | 2.15% | ||
| ROICexc | 2.31% | ||
| ROICexgc | 5.42% | ||
| OM | 5.18% | ||
| PM (TTM) | N/A | ||
| GM | 63.99% | ||
| FCFM | 1.89% |
ROA(3y)-2.68%
ROA(5y)-2.4%
ROE(3y)-7.46%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y37.89%
ROICexcg growth 5Y4.3%
ROICexc growth 3Y45.07%
ROICexc growth 5Y7.68%
OM growth 3Y31.35%
OM growth 5Y5.5%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-0.68%
F-Score4
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 28.63 | ||
| Debt/EBITDA | 4.93 | ||
| Cap/Depr | 51.26% | ||
| Cap/Sales | 2.96% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 44.29% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.78 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z | 3.62 |
F-Score4
WACC8.35%
ROIC/WACC0.26
Cap/Depr(3y)42.06%
Cap/Depr(5y)43.23%
Cap/Sales(3y)2.8%
Cap/Sales(5y)3.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%260%
EPS Next Y126.84%
EPS Next 2Y75.59%
EPS Next 3Y50.72%
EPS Next 5Y46.79%
Revenue 1Y (TTM)7.44%
Revenue growth 3Y9.14%
Revenue growth 5Y7.06%
Sales Q2Q%15.26%
Revenue Next Year11.74%
Revenue Next 2Y11.27%
Revenue Next 3Y11.48%
Revenue Next 5Y11.19%
EBIT growth 1Y-22.98%
EBIT growth 3Y43.36%
EBIT growth 5Y12.95%
EBIT Next Year108.87%
EBIT Next 3Y43.35%
EBIT Next 5Y32.16%
FCF growth 1Y224.1%
FCF growth 3YN/A
FCF growth 5Y7.33%
OCF growth 1Y335.36%
OCF growth 3YN/A
OCF growth 5Y7.04%